Orkla ASA (ORK) Earnings Call Transcript & Summary

November 14, 2025

Oslo Bors NO Consumer Staples Food Products earnings 32 min

Earnings Call Speaker Segments

Annie Bersagel

executive
#1

Good morning, everyone, and welcome to the presentation of Orkla's results for the third quarter. I'm Annie Bersagel, Head of Investor Relations and Communications. Nils Selte, our President and CEO, will start by summarizing the quarter's highlights. Then Arve Regland, our CFO, will take a deeper dive into the financials. Nils will return with some concluding remarks before we move on to the Q&A. As a reminder, we'll first hold a video Q&A with analysts, and after that we'll take all the questions submitted through the web. Feel free to send in your questions online at any point. With that, Nils, I'll hand the floor over to you.

Nils Selte

executive
#2

Thanks, Annie, and good morning, everyone. During this quarter, we kept carrying out our active ownership model and capital allocation strategy. The emphasis is on strengthening the core business within the portfolio companies and putting money into opportunities that generate long-term value. To begin with a highlight for this quarter, in Q3, Orkla achieved 4.4% organic growth across our portfolio companies, while the volume mix made a positive contribution of 1.3%. Underlying EBIT adjusted growth rose by 1.1%. In this quarter, we observe a mixed picture across the portfolio companies. Adjusted earnings per share came in at NOK 1.85, up 9% year on year. We completed an IPO of Orkla India. At the Capital Markets Day in November 2023, I stated that we were starting an IPO readiness study. Last week, we hit a major milestone with Orkla India's IPO. That reflects a year of steady effort, and I take pride in the persistence our team in India and at headquarters has demonstrated in getting to this point. Since we acquired MTR Foods back in 2007, we have enjoyed an amazing journey that began with strong local brands and a strong local management team. Orkla India bought Eastern in 2021 and has steadily expanded the company into what it is today.

Nils Selte

executive
#3

I want to be clear about one thing: this IPO does not represent an exit for Orkla. Orkla is going to stay on as a committed major owner of the company. Now that Orkla India is a listed company, it has its own currency and the flexibility that comes along with that — a tool that will support growth over time. The proceeds from selling Orkla India give us an additional financial contribution on top of Orkla's robust cash flow from operation. To optimize the capital structure and return excess capital to shareholders in line with our capital allocation policy, we've decided to initiate a NOK 4 billion share buyback program. That program will begin on November 17th, 2025, and conclude by the end of December 2026 at the latest. Moving on to organic growth development for the consolidated portfolio companies shown here over the past two years. Nearly all of the portfolio companies contributed to growth in this quarter. Orkla Food Ingredients and Orkla India had the largest positive contribution to volume mix. Orkla Snacks was the largest positive contributor to price growth due to extraordinary cocoa price situations. Turning to a breakdown of the portfolio companies' performance, we see a more flattish development in the results this quarter compared to a strong quarter last year.

Nils Selte

executive
#4

Keeping our attention on creating value over the long term, we observe favorable underlying progress at a number of the companies. Profitability differed among our portfolio companies, and Arve will give a more detailed picture of the individual companies, but a few developments are worth mentioning. Jotun kept delivering strong results in this quarter, with double-digit underlying EBIT growth in local currencies, while maintaining the high margin levels. Orkla Food Ingredients delivered lower EBIT growth compared to past quarters. This led to a weaker development in the bakery segment, in addition to volume growth in lower margin categories in plant-based. The positive growth in the sweet segment continued. Excluding the impact from cocoa, Orkla Snacks continued to have a positive underlying development. Moving on, the 12-month, the 12 rolling months EBIT adjusted margin for the consolidated portfolio companies held at 10.3% in the third quarter, a 0.3% improvement year on year. This improvement was broad-based, with corresponding margin improvements in seven of the nine consolidated portfolio companies. In terms of input cost, the development remains polarized. We continue to expect raw materials prices in some to stabilize in 2025, excluding cocoa. Beyond 2025, we expect a continued polarized cost development across sourcing categories and portfolio companies, with an overall neutral cost outlook despite inflationary market sentiment.

Nils Selte

executive
#5

During our Capital Markets Day, we set out financial goals covering three years for the consolidated portfolio companies. I also noted at that time that the biggest value creation over the near term would come from lifting the performance of the portfolio we already hold. So far, the progress made by our portfolio companies impresses me: they have delivered an EBIT adjusted compound annual growth rate of 11.8%, margin expansion of 1.3 percentage points, and a 2 percentage point improvement in return on capital employed — every one of those in line with the financial target we set for this strategy period. That said, plenty of work is still ahead. In 2026 we will be entirely focused on delivering each of these goals, with particular attention on continued organic growth, cost management, and capital discipline. Hitting our 2024 to 2026 target is central to delivering top-tier long-term shareholder return, which is our overarching mission. I will now pass things to Arve, who will walk through the quarter in more detail. Thank you so far.

Arve Regland

executive
#6

Thanks, Nils, and good morning, everyone. I'll begin by walking through the income statement highlights for the third quarter. Operating revenue came in at NOK 17.9 billion, which is up 4% compared with a year earlier, and EBIT adjusted reached NOK 2 billion, an increase of 2%. Positive contributions came from lower cost at Orkla ASA as well as at the business service companies. Other expenses totaled NOK 401 million for the quarter, and the key items there were a write-down of NOK 240 million on trademarks in Orkla Health plus a write-down of NOK 130 million in the European Pizza Company, which matches the remaining goodwill tied to New York Pizza's German operations. Profit from associates, predominantly Jotun, amounted to NOK 603 million, up 10% versus the same period last year, and that brought profit before tax to NOK 2 billion. The gain over last year stems largely from the substantial impairment charges taken a year ago. As Nils noted, adjusted EPS was NOK 1.85 per share, up 9%. Cash flow from operations for the year to date was NOK 4.8 billion. We sit roughly NOK 400 million under last year's record, for two reasons: a working capital build-up driven by higher trade receivables and inventory, and higher net replacement investments, mainly in Orkla Foods, Orkla Food Ingredients, and Orkla Snacks. Those cover replacement projects at a number of factories, ERP projects, and new long-term leases.

Arve Regland

executive
#7

The dividend from Jotun is the same as last year, at NOK 948 million, and the second installment came in during the third quarter. Now, on the capital allocation bridge, I'll walk through the specific developments in the quarter. Expansion CapEx stands at roughly NOK 400 million year to date, and NOK 250 million of that was in the third quarter; the quarterly rise is mainly tied to greater production capacity at Orkla Snacks and Orkla Food Ingredients. Company purchases rose by approximately NOK 100 million, mostly because of the Bolton acquisition within Orkla Food Ingredients. Our balance sheet remains robust, with net debt of NOK 17.7 billion, which equals 1.7x EBITDA and 1.3x when Orkla Food Ingredients is excluded. Turning to more detail on the portfolio companies, we'll begin, as always, with Jotun — and please note that the figures and graphs for Jotun cover the end of August year to date, since Jotun does not publish Q3 results. I will, however, go through some highlights from the quarter. Operating revenue fell 2% in the quarter, excluding negative currency translation effects. Sales growth was +4%. This continues an ongoing trend, with revenue growth driven by higher volumes as well as increased premium sales in the decorative segment.

Arve Regland

executive
#8

EBITDA rose 6% for the quarter, and 12% when you strip out the currency effects tied to a stronger Norwegian krone. Two things helped: higher sales volumes and a better gross margin thanks to lower raw material costs. Jotun did record financial gains from currency hedging during the quarter, though that amount remains far below the negative hit to EBITDA caused by the stronger NOK. Our guidance was that Jotun would deliver 2025 results on par with last year. We still expect currency headwinds to weigh on growth year-over-year in the fourth quarter. That being said, with the strong underlying operational development so far this year, Jotun's contribution to Orkla's results for 2025 is tracking ahead of our outlook. Orkla Foods posted organic growth of 0.8%. The negative volume mix impact in Q3 was temporary, stemming from ERP modernization in the Czech Republic, where the go-live process caused challenges at our main warehouse and led to lost sales. Adjusting for that, volume mix growth was slightly positive for Orkla Foods overall. Orkla Foods Norway saw negative volume mix, yet with a significant improvement versus the second quarter. Market share in growth categories went up, in line with the strategy communicated at the Capital Markets Update.

Arve Regland

executive
#9

Growth in underlying EBIT reached 2.4%, mainly as a result of higher sales. Costs of inputs rose in the quarter, and Orkla Foods anticipates that elevated prices for beef, dairy, marine, and berries will persist into next year. At Orkla Snacks, organic growth came to 7.5%, all of it driven by price. Chocolate was the biggest contributor to that price growth, while also weighing on volumes. In the snacks category, organic growth was flat for the quarter, with biscuits adding a positive contribution. Underlying EBIT fell 8.4% versus a year earlier, reflecting the impact of higher cocoa prices. BUBS entered the U.S. market in September via a production and distribution agreement with Mount Franklin Foods. The U.S. launch of BUBS looked promising, yet it was not material to Orkla Snacks' P&L in the quarter. We anticipate a limited EBIT effect from BUBS over the coming quarters, as we keep investing in A&P and SG&A to support the rollout. Organic growth at Orkla Home and Personal Care was 0.9%, driven by continued volume mix growth in Norway and Sweden, partly offset by lower volume mix in contract manufacturing and Finland. Underlying EBIT growth was 7.6% versus a year earlier, primarily cost driven. Organic growth at Orkla Food Ingredients was 8.3%, of which 3.9% came from volume mix.

Arve Regland

executive
#10

The plant-based segment was behind the volume mix increase, yet this came from lower-margin items, so the effect on EBIT growth was limited. Bakery saw a volume mix decrease across business units, hit by weaker consumer sentiment and tougher competition. Underlying EBIT growth of 1.6% for the quarter reflected continued gains from sweet ingredients, which were offset by lost bakery volume and, as noted, thin margins in plant-based. Orkla Health posted organic growth of 2.5%, alongside volume mix growth of 1.6%. Wound care and food supplements in Europe were the biggest positive contributors. Those gains were offset by ongoing weakness in both oral care and functional personal care categories serving B2B customers. The decline in underlying EBIT came from contribution margin pressure, higher SG&A cost, and more advertising spend in food supplements. Mats Palmquist, the new CEO of Orkla Health, came on board in mid-August, and initiatives have been started to cut complexity and lift growth. We will identify the right opportunity in 2026 to give the capital markets an update on Orkla Health. Orkla India released its quarterly results yesterday, so I will just highlight a few points here. Keep in mind that Orkla India reports to the Indian stock exchanges in local currency under Indian accounting standards, and its financial year begins April 1st.

Arve Regland

executive
#11

Our reported quarterly figures follow IFRS, are stated in NOK, and are shown on a calendar-year basis. Organic operating revenue rose 4.3%, as volume growth was positive while price contributed a decline. Underlying EBIT fell 1.8%, reflecting higher advertising spend tied to the early festive season, transition costs linked to the recent sales tax reform in India, and the fact that Orkla India booked financial incentives from the government of India during the same quarter last year. If you set aside the effect of those government grants, underlying EBIT adjusted growth came in at 6.2%. At the European Pizza Company, organic growth for the quarter was 2.2%, with consumer sales rising in the Netherlands, Finland, and Poland. Underlying EBIT was up 7%, helped by consumer sales growth and cost control. Finally, Orkla House Care posted top-line organic growth in the quarter, whereas development in the Health and Sports Nutrition Group was flat. Both companies showed substantial profitability improvement versus the same quarter last year. With that, I'll hand it back to you, Nils, for the closing remarks.

Nils Selte

executive
#12

Thanks, Arve. We're now in the back half of our 2024 to 2026 strategy period, and I feel good about what we've accomplished on the three strategic pillars we laid out at our Capital Markets Day: generating organic value within our current portfolio, making the portfolio structure simpler, and carrying out structural transactions that add value. As we move into the final stretch of this strategy period, our commitment to those three remains firm. At the same time, we've begun work on our next strategy plan, which will steer Orkla through 2030. That effort is underway in close cooperation with our board and rests on the same principles of focus, discipline, and long-term value creation. We're eager to share the next strategy plan with the market near the end of 2026. To wrap up, I'd like to thank our people throughout Orkla and our portfolio companies for all their hard work, and our owners for their ongoing support. We head into Q4 determined to close the year on a strong note and confident about what lies ahead. There's more work ahead of us, but we're happy with the direction. Thanks for listening. Arve and I are glad to take your questions now.

Annie Bersagel

executive
#13

Thanks for joining us again. We’re set to start the Q&A portion now, so if you’d like to ask something, please raise your hand and I’ll bring you in. A quick note: please unmute your volume and switch your camera on. Håkon Nelson from Kepler Cheuvreux has our first question.

Håkon Nelson

analyst
#14

Hello, and thanks a lot for taking my questions. I've got two of my own. The first concerns Jotun, which turned in a very strong quarter. Could you expand on what mainly drove that healthy volume growth and margin performance, and do you view this kind of result as something you can sustain as we head into 2026? The second question is on the transformation and exit portfolio. How should we think about the assets that remain, particularly with respect to timing, and are there any businesses beyond those currently classed as transformation or exit that you might consider putting forward for strategic review or a possible sale should the right conditions come about?

Nils Selte

executive
#15

Let's begin with what Jotun asked. As we explained, Jotun's result and strong performance stem largely from higher volume as well as an improved gross margin. We've also noted, I believe, that our current guidance now sits ahead of what we guided for the full year 2024. We expect to come in somewhat above the guidance we gave early this year. At this point we don't want to provide guidance for 2026. I'd guess we'll return to that at the Q4 presentation. Could you repeat that? On the transformer exit portfolio, we're down to two companies remaining. We have never given guidance on structural deals. I think we'll hold to that policy and won't guide on any structural deals. That applies across the entire portfolio, so to speak.

Håkon Nelson

analyst
#16

Thanks.

Annie Bersagel

executive
#17

Ole Martin Westgaard of DNB Carnegie has the next question.

Ole Martin Westgaard

analyst
#18

Hello, and thank you for taking my questions. I’ll begin with a quick question about foods. You pointed out delivery problems in the Czech Republic during this quarter. To be clear, have those issues been resolved at this point, or will they also affect Q4?

Arve Regland

executive
#19

Those issues are settled now. It was a Q3 incident tied to the ERP system rollout, and we ran into some trouble in the main warehouse because of it, but by the close of Q3 that was resolved, so Q4 shouldn't see any impact from it.

Ole Martin Westgaard

analyst
#20

Yeah, regarding snacks, could you give us specifics on how much demand in snacks or, say, chocolate fell during Q3, and when should we expect that to level off — or has it already leveled off by now?

Arve Regland

executive
#21

Things have leveled off, though we aren't providing precise guidance on specific figures. As mentioned before, chocolate price increases have caused volume to drop by at least 10%. It's settling down, yet as you can see in the report, it's still clearly weighing on the year-over-year numbers.

Ole Martin Westgaard

analyst
#22

Yeah, just a quick question about the write-downs. My understanding is that most of this relates to Nutrilett. What's the book value of Nutrilett that remains on your balance sheet right now?

Arve Regland

executive
#23

Nutrilett is fully gone now, though that brand was just one of a number of Orkla Health trademarks that took a writedown this quarter. Alongside Nutrilett, a handful of other trademarks got consolidated under Sana-sol, which becomes the new lead brand for some of them. So what was written down is really a mix of several trademarks, and together that adds up to the figures I laid out.

Ole Martin Westgaard

analyst
#24

Right, and one final question about foods and snacks. Could you share your view on how market share moved during this quarter, and how much pressure you're seeing from private label competitors? I'll rejoin the queue after that. Thanks.

Nils Selte

executive
#25

Overall, I'd say we're fairly flat—more on the flattish side. When you look at the priority categories in foods, we're gaining share there. In the remaining food categories, we're roughly level. That also holds true, though there are some variations across the different snack categories, but taken together, it's more of a flat trend this quarter.

Ole Martin Westgaard

analyst
#26

Thanks.

Annie Bersagel

executive
#27

The next question on our list appears to come from Petter Nystrøm at ABG Sundal Collier.

Petter Nystrøm

analyst
#28

Thanks. I’ve just got one quick question, and that’s whether you could give us some perspective on how you expect raw material prices to trend in 2026 compared with 2025. Thank you.

Nils Selte

executive
#29

Right, I touched on this briefly in my presentation earlier this morning, and our expectation is development that's flat, cocoa prices included, as we head into 2026. That's how things look as of today.

Petter Nystrøm

analyst
#30

Thanks. Please get back in the queue.

Nils Selte

executive
#31

It's fragmented. You see large disparities across the categories, and the impact on individual portfolio companies could vary. Broadly speaking.

Annie Bersagel

executive
#32

I notice Håkon Fuglu has raised his hand, so if you have another question, go ahead.

Håkon Fuglu

analyst
#33

Thanks for taking my question. This is the first one. Yeah, I have a few, and I'll go through them one at a time. During the second quarter, you mentioned inventory rebalancing in food for a couple of your clients. Did that affect us at all this quarter too?

Arve Regland

executive
#34

The effect during this quarter was quite minimal.

Håkon Fuglu

analyst
#35

All right. Regarding your headquarters cost, those kept coming down quarter over quarter in this period as well. Would you say we're kind of arriving at a more normalized level now in this quarter?

Nils Selte

executive
#36

We aren’t necessarily looking to provide guidance on the headquarter cost, but I think in this quarter we’re seeing a decrease in FTEs within the IT part of Orkla IT AS, and we’re also seeing a decrease in the number of FTEs at the headquarter, along with a decrease in bonus cost because of how the share price developed in this quarter, but we don’t want to guide for going forward.

Håkon Fuglu

analyst
#37

Last question from me. Regarding your hero brands and how you're elevating them—now that you've worked through the health piece, what sort of impact do you expect for the rest of the portfolio companies there? Are you noticing anything from the ambitions you launched on the CMU?

Nils Selte

executive
#38

Right. So putting new approaches into practice for how you actually operate a portfolio of different brands requires a lot of time, and it also takes time before that shows up in your performance. I think every company is now adopting this new way of thinking, and at the Capital Markets Update in May this year we presented with snack and food how they are working on it. This work is ongoing. As we have said, we see progress in prioritized categories in food over the last few quarters, and I think that is a good sign that this will work, and it is working, but it takes time before it hits the P&L, so to speak.

Håkon Fuglu

analyst
#39

Thanks. I’ll get back into the queue.

Annie Bersagel

executive
#40

Our next question comes from Ole Martin Westgaard at DNB Carnegie, as I see it.

Ole Martin Westgaard

analyst
#41

Yes, I have another question as well. Regarding the marketing spend you had this quarter, how did it compare year on year, and what would the underlying margin improvement be once marketing spend is adjusted for?

Arve Regland

executive
#42

We haven’t provided a specific figure for that, but compared with last year it is fairly flattish.

Ole Martin Westgaard

analyst
#43

Okay. And then regarding BUBS, could you elaborate a little on how you view BUBS’s performance in Q3 compared with what you expected? Has that shifted in any way how you see the appeal of the U.S. market?

Arve Regland

executive
#44

No — in the U.S., it's still early days, as you know. We said this in the report too: the launch is promising in the U.S., though its effect on the third-quarter numbers is limited, since we launched at the end of that quarter. We're also very keen now to back that rollout, which means supporting sales with SG&A resources as well as A&P. Given all that, it's promising, but I wouldn't count on a huge impact to the P&L in the quarters ahead, because of the efforts we're putting behind the rollout.

Nils Selte

executive
#45

When it comes to BUBS, we're going to put money into the U.S. market with a long-term view.

Ole Martin Westgaard

analyst
#46

Appreciate it.

Annie Bersagel

executive
#47

That appears to be the final video question. We'll now move on to questions submitted online. It looks like a few have come in from Marcela Klang at Svenska Handelsbanken. Marcela's first question concerns strategy. Could you give some indication of the ongoing strategic plan that you'll present around the end of 2026? Which areas are you considering targeting? Real estate, M&A?

Nils Selte

executive
#48

My view is that it's far too soon for that. This is something we've only just begun with the board. Discussions are ongoing, and we've put together a plan for building a solid strategy going forward, looking ahead to 2030. As part of this work, we'll also go deep into the portfolio companies, and each of them will produce its own full potential plan along with strategy plans. Until we can see the whole picture, we aren't in a position to offer any guidance to the market. We'll come back at the end of 2026 with a new Capital Markets Day to lay out our strategy for 2030.

Annie Bersagel

executive
#49

Marcela's final question is this: do you anticipate that the NOK 4 billion share buyback program will be distributed evenly over Q1, Q2, Q3, and Q4 of 2026, or will more of it land in the first half?

Arve Regland

executive
#50

So the buyback will be carried out under the MAR rules, which means the amount we purchase has to avoid moving the share price — so no more than 25% of volume during recent periods. That means however long it takes is how long it takes, and we won't be giving clear guidance on the number of months required, but clearly accumulating that volume in the market is going to take some time.

Annie Bersagel

executive
#51

Looks like that was the last question from the web. Before we wrap up, I want to remind everyone that our fourth-quarter results will be reported on February 12th. So with that, thanks for being with us, and have a great day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Orkla ASA transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Orkla ASA earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Orkla ASA or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.